SCYX SCYNEXIS, Inc. Stock Quote

SCYX [NASD]

Healthcare | Drug Manufacturers - Specialty & Generic | USA

Index	-	P/E	-	EPS (ttm)	-1.21	Insider Own	1.30%	Shs Outstand	32.05M	Perf Week	-1.45%
Market Cap	84.90M	Forward P/E	-	EPS next Y	-1.43	Insider Trans	23.88%	Shs Float	28.36M	Perf Month	42.63%
Income	-33.60M	PEG	-	EPS next Q	-0.59	Inst Own	44.30%	Short Float	3.82%	Perf Quarter	44.92%
Sales	1.80M	P/S	47.17	EPS this Y	75.80%	Inst Trans	-0.37%	Short Ratio	7.71	Perf Half Y	-47.58%
Book/sh	1.21	P/B	2.24	EPS next Y	24.30%	ROA	-29.10%	Target Price	19.00	Perf Year	-57.92%
Cash/sh	-	P/C	-	EPS next 5Y	-	ROE	-89.60%	52W Range	1.70 - 8.10	Perf YTD	-55.57%
Dividend	-	P/FCF	-	EPS past 5Y	39.80%	ROI	-74.00%	52W High	-66.54%	Beta	2.06
Dividend %	-	Quick Ratio	7.80	Sales past 5Y	119.70%	Gross Margin	77.20%	52W Low	59.41%	ATR	0.18
Employees	56	Current Ratio	7.90	Sales Q/Q	-94.20%	Oper. Margin	-	RSI (14)	66.20	Volatility	6.93% 9.15%
Optionable	Yes	Debt/Eq	1.14	EPS Q/Q	6.20%	Profit Margin	-	Rel Volume	0.59	Prev Close	2.69
Shortable	Yes	LT Debt/Eq	1.14	Earnings	May 12 BMO	Payout	-	Avg Volume	140.42K	Price	2.71
Recom	1.70	SMA20	14.78%	SMA50	28.69%	SMA200	-33.67%	Volume	83,218	Change	0.74%

Jan-22-21

Initiated

Guggenheim

Buy

$25

Jan-06-21

Initiated

Cantor Fitzgerald

Overweight

$30

Jul-11-18

Upgrade

Needham

Hold → Buy

Jun-27-18

Initiated

Maxim Group

Buy

Oct-24-17

Initiated

Guggenheim

Buy

Jul-10-17

Initiated

ROTH Capital

Buy

$8.50

May-09-17

Downgrade

Needham

Buy → Hold

Mar-03-17

Reiterated

RBC Capital Mkts

Outperform

$15 → $11

Oct-20-16

Initiated

H.C. Wainwright

Buy

$14

Oct-07-16

Upgrade

WBB Securities

Buy → Strong Buy

Oct-03-16

Resumed

Brean Capital

Buy

Aug-17-16

Initiated

Guggenheim

Buy

$15

Aug-09-16

Upgrade

WBB Securities

Speculative Buy → Buy

Aug-09-16

Reiterated

Needham

Buy

$16 → $10

Mar-28-16

Initiated

Brean Capital

Buy

$16

Dec-29-15

Initiated

WBB Securities

Strong Buy

Dec-29-15

Initiated

WBB Securities

Speculative Buy

Nov-16-15

Reiterated

RBC Capital Mkts

Outperform

$18 → $17

Jun-10-15

Initiated

Needham

Buy

$16

May-29-14

Initiated

RBC Capital Mkts

Outperform

$17

Aug-09-22 08:30AM	SCYNEXIS to Report Second Quarter 2022 Financial results and Provide a Corporate Update on August 15 GlobeNewswire -6.90%
Aug-04-22 08:30AM	SCYNEXIS Presents Positive Data from Its Pivotal Phase 3 CANDLE Study of Oral Ibrexafungerp for Prevention of Recurrent Vaginal Yeast Infections During the 2022 IDSOG Annual Meeting GlobeNewswire +8.70%
Aug-01-22 08:30AM	SCYNEXIS Announces U.S. Food and Drug Administration Acceptance and Priority Review of the Supplemental New Drug Application for BREXAFEMME® (ibrexafungerp tablets) for Prevention of Recurrent Vaginal Yeast Infections GlobeNewswire
Jul-19-22 08:30AM	SCYNEXIS Presents Positive Data from Phase 3 CANDLE Nested Sub-Study Investigating Ibrexafungerp in Women with Recurrent Yeast Infections Who Failed Fluconazole During the ISSVD XXVI World Congress and International Vulvovaginal Disease Update GlobeNewswire
Jul-14-22 08:30AM	SCYNEXIS to Present Data from the CANDLE Nested Sub-Study of Ibrexafungerp During the International Society for the Study of Vulvovaginal Disease (ISSVD) XXVI World Congress and International Vulvovaginal Disease Update GlobeNewswire
Jun-29-22 07:06AM	The past five years for SCYNEXIS (NASDAQ:SCYX) investors has not been profitable Simply Wall St.
Jun-23-22 08:30AM	SCYNEXIS Announces Initiation of New Phase 3b Study (VANQUISH) to Evaluate Oral Ibrexafungerp as a Treatment for Complicated Vulvovaginal Candidiasis (VVC) in Patients Who Failed to Respond to Treatment with Fluconazole GlobeNewswire
Jun-08-22 08:30AM	SCYNEXIS Announces Submission of Supplemental New Drug Application of BREXAFEMME® (ibrexafungerp tablets) to the U.S. Food and Drug Administration for an Expanded Indication for the Prevention of Recurrent Vaginal Yeast Infections GlobeNewswire
Jun-03-22 04:05PM	SCYNEXIS Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
May-20-22 08:30AM	SCYNEXIS to Present at Upcoming H.C. Wainwright Global Investment Conference GlobeNewswire
May-12-22 08:35AM	Scynexis (SCYX) Reports Q1 Loss, Misses Revenue Estimates Zacks
07:00AM	SCYNEXIS Reports First Quarter 2022 Financial Results and Provides Corporate Update GlobeNewswire
May-10-22 08:30AM	SCYNEXIS Presents New Interim Positive Data of Ibrexafungerp for Refractory Vulvovaginal Candidiasis from Ongoing Phase 3 FURI Study at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting GlobeNewswire
May-05-22 08:30AM	SCYNEXIS to Report First Quarter 2022 Financial Results and Provide a Corporate Update on May 12 GlobeNewswire -6.90%
May-04-22 08:30AM	SCYNEXIS to Present New Data of Ibrexafungerp for Refractory Vulvovaginal Candidiasis from Ongoing Phase 3 FURI Study at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting GlobeNewswire
Apr-30-22 08:55AM	The CEO, President & Director of SCYNEXIS, Inc. (NASDAQ:SCYX), Marco Taglietti, Just Bought 68% More Shares Simply Wall St.
Apr-27-22 08:30AM	SCYNEXIS Presents Data Analyses Showing Ibrexafungerps Potential to Fight Invasive Candidiasis and Candidemia, Including Infections Caused by Candida Auris, During the 32nd Annual European Congress of Clinical Microbiology & Infectious Diseases GlobeNewswire
Apr-26-22 05:18PM	SCYNEXIS Announces Closing of $45 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants GlobeNewswire
Apr-22-22 08:15AM	SCYNEXIS Announces Pricing of $45 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants GlobeNewswire -25.80%
08:00AM	SCYNEXIS Announces Positive Interim Data from Phase 3 FURI and CARES Studies Highlighting Oral Ibrexafungerp's Potency Against Severe Fungal Infections GlobeNewswire
Apr-21-22 04:01PM	SCYNEXIS Announces Launch of Public Offering of Common Stock and Warrants GlobeNewswire
Apr-20-22 08:30AM	SCYNEXIS to Present Positive Interim Data from Ongoing FURI and CARES Studies at the 32nd Annual European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) Being Held April 23-26 in Lisbon, Portugal GlobeNewswire
Apr-19-22 08:30AM	SCYNEXIS Secures Additional Commercial Insurance Formulary Coverage for BREXAFEMME® (ibrexafungerp tablets), Providing Access to an Estimated 93 Million Commercially-Insured Lives GlobeNewswire
Apr-09-22 08:03AM	Revenue Downgrade: Here's What Analysts Forecast For SCYNEXIS, Inc. (NASDAQ:SCYX) Simply Wall St.
Apr-04-22 09:59AM	SCYNEXIS to Participate in Upcoming April Womens Health Medical Conferences GlobeNewswire
Mar-31-22 01:37PM	What Type Of Shareholders Make Up SCYNEXIS, Inc.'s (NASDAQ:SCYX) Share Registry? Simply Wall St.
Mar-29-22 08:15AM	Scynexis (SCYX) Reports Q4 Loss, Lags Revenue Estimates Zacks -12.98%
07:00AM	SCYNEXIS Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update GlobeNewswire
Mar-24-22 08:30AM	SCYNEXIS to Report Fourth Quarter and Full Year 2021 Financial Results and Provide a Business Update GlobeNewswire
Mar-08-22 08:30AM	SCYNEXIS Named to Fast Companys 2022 Top 50 List of the Worlds Most Innovative Companies GlobeNewswire
Mar-04-22 05:00PM	SCYNEXIS Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Mar-02-22 08:30AM	SCYNEXIS to Participate in Upcoming Scientific Conferences and Events GlobeNewswire
Feb-13-22 07:43AM	Some Analysts Just Cut Their SCYNEXIS, Inc. (NASDAQ:SCYX) Estimates Simply Wall St.
Feb-10-22 07:36AM	SCYNEXIS Announces Positive Results from Its Pivotal Phase 3 CANDLE Study of Oral Ibrexafungerp for Prevention of Recurrent Vaginal Yeast Infections, Clearing the Way for Regulatory Submission and Potential Approval of Additional Indication by End of 2022 GlobeNewswire
Feb-03-22 04:15PM	SCYNEXIS Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Jan-20-22 10:13AM	The past five years for SCYNEXIS (NASDAQ:SCYX) investors has not been profitable Simply Wall St.
Jan-06-22 01:03PM	SCYNEXIS to Participate in Upcoming January Investor Conferences GlobeNewswire
Dec-22-21 08:30AM	SCYNEXIS Reports the Exercise of Warrants Totalling $21.1 Million GlobeNewswire -9.61%
Dec-20-21 08:30AM	BREXAFEMME® (ibrexafungerp tablets) Added to Major National Formulary, Providing Access for Millions More Commercially Insured Patients GlobeNewswire +6.23%
Dec-15-21 08:30AM	European Medicines Agency Grants Orphan Medicinal Product Designation for SCYNEXIS Innovative Antifungal Ibrexafungerp for the Indication of Invasive Candidiasis GlobeNewswire +7.09%
Dec-06-21 07:00AM	SCYNEXIS Announces Agreement with FDA on Innovative Strategy for Approval of Oral Ibrexafungerp for Treatment of Invasive Candidiasis GlobeNewswire
Dec-03-21 04:30PM	SCYNEXIS Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
08:43AM	SCYNEXIS Reports the Exercise of Warrants Totalling $7.9 Million GlobeNewswire
Dec-01-21 10:37AM	BREXAFEMME® (Ibrexafungerp Tablets) Receives 2021 Popular Science Best of Whats New Award in the Health Category GlobeNewswire -8.94%
08:29AM	Is SCYNEXIS (NASDAQ:SCYX) Using Debt Sensibly? Simply Wall St.
Nov-29-21 08:30AM	SCYNEXIS to Host Ibrexafungerp Hospital Pipeline Update Call and KOL Webcast for Investors on December 6 GlobeNewswire
Nov-23-21 08:30AM	SCYNEXIS Pivotal Phase 3 VANISH-306 Trial Results Published in the International Journal of Obstetrics and Gynaecology (BJOG) Demonstrate Statistical Superiority of BREXAFEMME® (Ibrexafungerp Tablets) Over Placebo for Vaginal Yeast Infection GlobeNewswire +7.39%
Nov-18-21 05:18PM	Michael Burry dumped just about everything in Q3 to guard against the 'mother of all crashes' but he did purchase 3 interesting new holdings MoneyWise -7.49%
Nov-10-21 10:15AM	Scynexis (SCYX) Reports Q3 Loss, Tops Revenue Estimates Zacks
07:34AM	SCYNEXIS Reports Third Quarter 2021 Financial Results and Provides Corporate Update GlobeNewswire
Nov-09-21 08:30AM	SCYNEXIS Announces Successful Completion of Phase 1 Trial Evaluating Intravenous (IV) Formulation of Ibrexafungerp GlobeNewswire
Nov-03-21 08:30AM	SCYNEXIS to Provide a Corporate Update and Report Third Quarter 2021 Financial Results on November 10 GlobeNewswire
Oct-21-21 08:30AM	SCYNEXIS Pivotal Phase 3 VANISH-303 Trial Results Published in Clinical Infectious Diseases Demonstrate Significant Superiority of Ibrexafungerp Over Placebo for Treatment of Vaginal Yeast Infection GlobeNewswire
Oct-13-21 08:30AM	SCYNEXIS to Present Pooled Data Analysis Results Demonstrating Consistent Efficacy and Safety Outcomes Across Two Phase 3 VANISH Clinical Trials of Oral Ibrexafungerp Therapy for Vaginal Yeast Infection at October Medical Conferences GlobeNewswire
Oct-11-21 08:30AM	SCYNEXIS Announces Preclinical Data at the 10th Trends in Medical Mycology Meeting Supporting Potential of Ibrexafungerp to Treat Mucormycosis GlobeNewswire
Oct-07-21 08:00AM	SCYNEXIS to Present Clinical Data from Ongoing FURI and CARES Studies at the 10th Trends in Medical Mycology Meeting Showing Oral Ibrexafungerp Provides a Favorable Therapeutic Response in Patients with Severe Fungal Infections GlobeNewswire
Sep-30-21 08:00AM	Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2021 PR Newswire
Sep-29-21 08:30AM	SCYNEXIS Presents Interim Analysis from FURI at Virtual IDWeek 2021 Showing Favorable Therapeutic Response in Severe Hospital-Based Fungal Infections Treated with Oral Ibrexafungerp GlobeNewswire
Sep-23-21 08:30AM	SCYNEXIS to Present Data on Oral Ibrexafungerp at IDWeek 2021 from Interim Analyses of Phase 3 FURI Clinical Trial Showing Therapeutic Response Rates in Patients with Mucocutaneous and Invasive Fungal Infections GlobeNewswire
Sep-22-21 08:30AM	SCYNEXIS Announces U.S. Availability of BREXAFEMME® (ibrexafungerp tablets), the First New Antifungal Class of Therapy Approved by the U.S. FDA for Vaginal Yeast Infections in More Than 20 Years GlobeNewswire
Sep-20-21 11:38AM	What Kind Of Shareholders Own SCYNEXIS, Inc. (NASDAQ:SCYX)? Simply Wall St. -6.10%
Sep-13-21 08:30AM	SCYNEXIS Announces Hansoh Pharmas Application to National Medical Products Administration (NMPA) in China for Phase 3 Trial of Ibrexafungerp for Treatment of Vulvovaginal Candidiasis (VVC) GlobeNewswire -7.70%
Sep-08-21 08:30AM	SCYNEXIS to Participate in Upcoming Investor Conferences GlobeNewswire
Aug-16-21 08:00AM	SCYNEXIS Reports Second Quarter 2021 Financial Results and Provides Corporate Update GlobeNewswire
Aug-13-21 05:15AM	Investors in SCYNEXIS (NASDAQ:SCYX) have unfortunately lost 77% over the last five years Simply Wall St.
Aug-05-21 08:00AM	Acurx Pharmaceuticals Joins the Antimicrobials Working Group PR Newswire
Aug-02-21 05:00PM	SCYNEXIS Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Jul-29-21 08:00AM	SCYNEXIS Announces Two Oral Presentations on Pooled Data from the BREXAFEMME (Ibrexafungerp tablets) Phase 3 VANISH Program Demonstrating Consistent Efficacy in the Treatment for Vaginal Yeast Infections at the IDSOG 2021 Virtual Annual Meeting GlobeNewswire
Jul-12-21 08:00AM	SCYNEXIS Announces Three Oral Presentations of Ibrexafungerp Demonstrating Clinical and In Vitro Activity Against Candida Species at the 31st ECCMID GlobeNewswire
Jul-07-21 08:30AM	SCYNEXIS to Present at Ladenburg Thalmanns Virtual 2021 Healthcare Conference GlobeNewswire
Jul-02-21 04:01PM	SCYNEXIS Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Jun-23-21 08:30AM	SCYNEXIS to Present Commercial Launch Update for BREXAFEMME® (ibrexafungerp tablets) GlobeNewswire +5.26%
Jun-22-21 09:48PM	Is SCYX Stock A Buy Here? Insider Monkey
Jun-11-21 08:30AM	SCYNEXIS to Present at the BIO Digital International Convention 2021 GlobeNewswire
Jun-09-21 08:30AM	SCYNEXIS Confirms that BREXAFEMME® (ibrexafungerp tablets) Qualifies for 10 Years of Regulatory Exclusivity for Vaginal Yeast Infections GlobeNewswire
Jun-08-21 11:07AM	Crestone Joins Antimicrobials Working Group PR Newswire
Jun-02-21 07:30AM	SCYNEXIS Announces FDA Approval of BREXAFEMME® (ibrexafungerp tablets) as the First and Only Oral Non-Azole Treatment for Vaginal Yeast Infections GlobeNewswire -15.25%
May-17-21 08:30AM	SCYNEXIS Reports First Quarter 2021 Financial Results and Provides Corporate Update GlobeNewswire +12.66%
May-14-21 08:30AM	SCYNEXIS Secures Term Loan Facility for up to $60 Million with Hercules Capital and Silicon Valley Bank GlobeNewswire
May-11-21 08:30AM	SCYNEXIS Appoints Accomplished Commercial Executive Christine Coyne as Chief Commercial Officer to Lead the Brexafemme® Launch GlobeNewswire +7.38%
Apr-30-21 08:00AM	SCYNEXIS Presents Data at 2021 ACOG Demonstrating the Positive Outcome and Sustained Response of Investigational Oral Ibrexafungerp (Brexafemme) in Difficult-to-Treat Patients with Vaginal Yeast Infections GlobeNewswire
Apr-20-21 08:00AM	SCYNEXIS to Present Two Ibrexafungerp (Brexafemme) Posters at the 2021 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting GlobeNewswire
Apr-12-21 09:21AM	SCYNEXIS (NASDAQ:SCYX) Has Debt But No Earnings; Should You Worry? Simply Wall St.
Mar-29-21 08:20AM	SCYNEXIS Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update GlobeNewswire -5.23%
Mar-02-21 07:30AM	SCYNEXIS Announces Positive Results from Interim Analyses of Ongoing Phase 3 Studies (FURI and CARES), Demonstrating Oral Ibrexafungerp's Ability to Treat Severe Fungal Infections in the Hospital Setting GlobeNewswire +6.56%
Feb-25-21 04:15PM	SCYNEXIS to Participate in Maxim Groups Late Stage Innovations in Womens Health Virtual Event GlobeNewswire -5.17%
Feb-17-21 10:04AM	UTILITY Therapeutics Joins Antimicrobials Working Group PR Newswire
08:15AM	SCYNEXIS Announces Licensing Agreement and Strategic Partnership with Hansoh Pharma for Rights to Ibrexafungerp in Greater China GlobeNewswire
08:15AM	SCYNEXIS and Hansoh Pharma Announce Licensing Agreement and Strategic Partnership for Ibrexafungerp in Greater China Business Wire
Feb-09-21 07:30AM	Aquestive Therapeutics Strengthens Board of Directors with Appointments of Julie Krop, M.D., and Marco Taglietti, M.D., and Announces Resignation of Douglas K. Bratton from Board of Directors GlobeNewswire
Dec-27-20 11:20PM	Trade Alert: The CEO, President & Director Of SCYNEXIS, Inc. (NASDAQ:SCYX), Marco Taglietti, Has Just Spent US$250k Buying 57% More Shares Simply Wall St.
Dec-23-20 11:35AM	Insider Buys SCYNEXIS Shares Benzinga +6.82%
Dec-22-20 08:00AM	SCYNEXIS Announces Closing of $85 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants GlobeNewswire +6.54%
Dec-17-20 09:29AM	SCYNEXIS Announces Pricing of $85 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants GlobeNewswire -19.10%
Dec-16-20 04:21PM	SCYNEXIS Announces Launch of $50 Million Public Offering of Common Stock and Warrants GlobeNewswire
Dec-10-20 08:00AM	SCYNEXIS Announces Advancement of Ibrexafungerps Intravenous Formulation to Clinical Stage and Provides Further Updates on its Clinical Studies in Patients with Life-Threatening Fungal Infections GlobeNewswire
Dec-07-20 08:00AM	SCYNEXIS Announces FDA Acceptance and Priority Review of New Drug Application for Oral Ibrexafungerp for the Treatment of Vaginal Yeast Infections GlobeNewswire +11.67%
Nov-27-20 02:36PM	Is SCYNEXIS Inc (SCYX) A Good Stock To Buy? Insider Monkey
Nov-24-20 09:35AM	SCYNEXIS to Participate in Piper Sandler and Evercore ISI Conferences GlobeNewswire
Nov-09-20 02:21PM	How Much Is SCYNEXIS' (NASDAQ:SCYX) CEO Getting Paid? Simply Wall St. +9.39%

SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Taglietti Marco	Chief Executive Officer	Apr 26	Buy	3.00	75,000	225,000	272,068	Apr 28 07:25 AM
Sukenick Scott	General Counsel	Apr 26	Buy	3.00	3,500	10,500	53,499	Apr 28 07:24 AM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience